ArticleStem cells international2026
Prognostic Significance of SGK1 Expression in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Study.
Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correlation Between SGK1 Expression Level and Multiple Myeloma Progression After Autologous Hematopoietic Stem Cell Transplantation.Biochemical genetics · 2026Article
- Prognostic Significance of SGK1 Expression in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Study.Stem cells international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This research attempts to assess the prognostic significance of serum/glucocorticoid-regulated kinase 1 (SGK1) expression in peripheral blood mononuclear cells (PBMCs) of multiple myeloma (MM) individuals undergoing autologous hematopoietic stem cell transplantation (AHSCT) compared to traditional minimal residual disease (MRD) and serum free light chain (sFLC) assessments. Methods: A single-center, retrospective study was carried out involving 85 MM individuals who underwent AHSCT. SGK1 gene expression was measured in PBMCs using quantitative real-time PCR (qRT-PCR) at baseline and at defined post-transplant intervals. Concurrently, MRD status was assessed using multiparameter flow cytometry (MFC) and sFLC levels were measured. Individuals were seen for a median of 36 months post-transplant. ROC curve analysis was employed to assess the predictive power of SGK1 expression, MRD, and sFLC for relapse. Results: SGK1 gene expression demonstrated dynamic changes in AHSCT, with levels decreasing in all risk groups, reflecting reductions in disease burden. Quantitative analysis showed that the predictive efficacy of SGK1, utilizing the area under the receiver operating characteristic (ROC) curve (area under the curve [AUC]), was highly comparable to that of MRD assessments, with SGK1 achieving an AUC of 0.86, closely approximating the MRD AUC of 0.88. Persistent high SGK1 expression, particularly discernible in individuals harboring high-risk (HR) cytogenetic profiles, was considerably associated with an elevated risk of relapse (hazard ratio for high vs. low SGK1 expression: 2.7; 95% CI: 1.4-5.3; Conclusion: SGK1 gene expression in PBMCs serves as a promising, minimally invasive biomarker for relapse prediction in MM individuals undergoing AHSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.